Roche reports sales of 14.4 billion Swiss francs for the first quarter of 2024, down 6% on a reported basis, but up 2% at constant exchange rates, driven by strong growth in new drugs and diagnostics.

Excluding Covid-19-related products, sales rose by 7%', says the Swiss healthcare group, adding that 'going forward, there will be no further significant impact from the decline in Covid-19-related sales'.

Roche is therefore confident of achieving sales growth 'in the mid-single digits' this year (at constant exchange rates), and confirms its outlook for 2024.

Copyright (c) 2024 CercleFinance.com. All rights reserved.